ArticleRheumatology (Oxford, England)2025
High prevalence of MASLD in psoriasis and psoriatic arthritis assessed with multiparametric magnetic resonance imaging.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prevalence of Metabolic-Dysfunction-Associated Steatotic Liver Disease in Patients with Psoriasis and Psoriatic Arthritis.Diagnostics (Basel, Switzerland) · 2026Article
- Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation.Biology · 2026Review
- Low Serum Adiponectin May Identify MASLD as a Comorbidity in Patients with Moderate-to-Severe Psoriasis.Psoriasis (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesPsoriatic disease (PsD) is a chronic inflammatory condition associated with obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH). We aimed to determine the prevalence of MASLD/MASH in a real-world psoriatic cohort using advanced imaging.
methodsCOLIPSO is a multicentre, prospective study of adults with PsD receiving standard systemic therapy in secondary care. Fifty participants underwent clinical assessments and non-invasive tests of liver health, including MRI-biomarkers of liver fibro-inflammation and fat content. These were compared with 360 individuals with PsD, with 150 controls without PsD (matched for age, sex, BMI and comorbidities) and 150 healthy controls from the UK Biobank and COVERSCAN studies. Associations were investigated with Spearman's rank correlations and multivariate linear regression models.
resultsThe prevalence of steatotic liver disease was 44% in the PsD group (aged 48 years, 58% male, BMI 29 kg/m2) and higher than in matched controls (25%, P = 0.02). MASH was prevalent in 22% of PsD patients (vs 3% in matched controls, P < 0.001). Thirteen of the 24 (54%) individuals with PsD and liver disease had normal liver function blood tests. No significant difference in levels of liver disease was observed between those with or without prior exposure to methotrexate.
conclusionsIndividuals with PsD exhibit higher prevalence of MASLD and MASH that was missed by blood tests and was present even in individuals with no methotrexate exposure. These findings underscore the importance of routine MASLD screening in this population with more sensitive tools, such as multi parametric MRI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.